Several lines of evidence have suggested that the Wnt/PKC signaling pathway was aberrantly activated in some cancer types, in which Wnt5a might activate this signaling and was responsible for metastasis and chemoresistance in cancers in part through activation of Wnt/β-cateinin signaling [34–37]. Here, PRRT2 is linked to cancer.